Tabel 2 angiver de bivirkninger, der forekom med større hyppighed (forskel > 0, 2%) i gruppen af abataceptbehandlede patienter end blandt de placebobehandlede patienter.
Listed in Table 2 are adverse drug reactions that occurred with greater frequency (difference > 0.2%) in abatacept-treated patients than in placebo-treated patients.